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Abstract
Background: The paper reports a quantitative analysis of the perfusion maps of 22 patients,
affected by gliomas or by metastasis, with the aim of characterizing the malignant tissue with
respect to the normal tissue. The gold standard was obtained by histological exam or nuclear
medicine techniques. The perfusion scan provided 11 parametric maps, including Cerebral Blood
Volume (CBV), Cerebral Blood Flow (CBF), Average Perfusion (Pmean) and Permeability-surface
area product (PS).
Methods: The perfusion scans were performed after the injection of 40 ml of non-ionic contrast
agent, at an injection rate of 8 ml/s, and a 40 s cine scan with 1 s interval was acquired. An expert
radiologist outlined the region of interest (ROI) on the unenhanced CT scan, by using a home-made
routine. The mean values with their standard deviations inside the outlined ROIs and the
contralateral ROIs were calculated on each map. Statistical analyses were used to investigate
significant differences between diseased and normal regions. Receiving Operating Characteristic
(ROC) curves were also generated.
Results: Tumors are characterized by higher values of all the perfusion parameters, but after the
statistical analysis, only the PS, PatRsq (Patlak Rsquare) and Tpeak (Time to Peak) resulted significant.
ROC curves, confirmed both PatRsq and PS as equally reliable metrics for discriminating between
malignant and normal tissues, with areas under curves (AUCs) of 0.82 and 0.81, respectively.
Conclusion: CT perfusion is a useful and non invasive technique for evaluating brain neoplasms.
Malignant and normal tissues can be accurately differentiated using perfusion map, with the aim of
performing tumor diagnosis and grading, and follow-up analysis.
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Background
CT perfusion is a technique that provides information on
brain hemodynamics by analyzing the first passage into
the cerebral vessels of an intravenous contrast bolus. The
technique can be rapidly performed using a multislice CT
scanner, capable of producing the cine mode scan with
the aid of an automatic injector; the perfusion maps are
generated by a workstation running dedicated software.
Modern imaging systems, being completely digital, are
suitable for quantitative analyses [1-3].
In particular, CT-Perfusion imaging permits a qualitative
and quantitative evaluation of the brain perfusion by
mapping cerebral blood flow (CBF) and cerebral blood
volume (CBV).
The Perfusion-CT technique has been found to be useful
in the evaluation of cerebral ischemia and infarction, but
recent studies have investigated the role of perfusion maps
for evaluating brain neoplasms, because there is growing
interest in the non-invasive assessment of tumor vascular-
ity [4]. The rationale for the use of CT Perfusion for neo-
plasms is that the technique provides information about
tumor angiogenesis. The increase of angiogenic activity
and neovascularization in the neoplasms results in an
increase of microvascular permeability and CBV, related
to the presence of immature, disrupted or absent vessels of
the blood-brain-barrier (BBB).
In recent studies [5-9], CT-Perfusion imaging of brain
tumors has been shown to be helpful for assessing preop-
erative tumor grade, differentiating between the tumor
enhancement and the radiation necrosis; evaluating the
response to anti-angiogenetic agents as well as guiding
biopsy procedure, when the biopsy target is chosen on the
basis of the identification of the hypervascularization area
inside heterogeneous tumors.
The aim of this study was to use perfusion maps to char-
acterize malignant versus normal tissue, in order to select
those parameters to be used in subsequent clinical studies
for a more accurate diagnosis.
Methods
Patients
A 4 slices helical CT scanner (Somatom Plus 4 Volume
Zoom; Siemens Medical Systems, Erlangen, Germany)
was used and perfusion CT was incorporated into the
patients' conventional CT examination. The study was
approved by our institutional review board and informed
consent was obtained from all patients.
A total of 22 patients were enrolled in this study: 12
patients affected by malignant gliomas (7 Glioblastoma
(GBM), 2 by Anaplastic Astrocytoma (AA), 2 by Oligoden-
drogliomas), 10 patients affected by metastases (from 6
breast, 2 lung, and one melanoma and maxillary sinus
cancers). The patient's clinical and histological informa-
tion is reported in Table 1.
CT-Perfusion was performed in 11 patients for the differ-
ential diagnosis between a tumor relapse or a radiation
necrosis on the basis of morphologic imaging (MR, Mag-
netic Resonance); in 8 patients during post radiation and/
or chemotherapy follow-up; in 3 patients, before diagno-
sis, to evaluate the area of maximum vascularization at the
site of the stereotactic biopsy.
The diagnostic status of the patients should be known
with certainty (Gold Standard). Depending on the clinical
task, histopathological exam, follow-up of the lesion,
diagnosis by a panel of experts or information about
cause-of-death could all be useful to define the gold stand-
ard. In particular, the length of the follow-up study is
based on reasonable estimates of cancer growth rates.
Because the present study is retrospective, the method
used to determine the patient status depends on a single
case. All the primary tumors were detected through histo-
logical diagnosis, surgical resection or stereotactic biopsy.
In some cases, where the diagnosis was undefined, the
gold standard was obtained by nuclear medicine tech-
niques: SPECT (Single Photon Emission Computed Tom-
ography) in 4 patients and PET-CT (Positron Emission
Table 1: Clinical and histological information of the group of 22 
patients included in the study
Patient no. Sex Pathology Patient status
1 M Melanoma Recurrence
2 F Breast Cancer Recurrence
3 F Breast Cancer Recurrence
4 F Breast Cancer Recurrence
5 M Maxillary sinus Metastasis
6 F Breast Cancer Metastasis
7 F Breast Cancer Metastasis
8 M Glioblastoma Recurrence
9 M Astrocytoma Recurrence
10 M Oligodendroglioma Recurrence
11 M Glioblastoma Recurrence
12 M Glioblastoma Recurrence
13 M Glioblastoma Recurrence
14 M Glioblastoma Recurrence
15 M Glioblastoma Recurrence
16 M Glioblastoma Recurrence
17 M Lung Cancer Recurrence
18 M Astrocytoma Recurrence
19 M Breast Metastasis
20 M Oligodendroglioma Recurrence
21 M Lung Metastasis
22 F Lung MetastasisJournal of Experimental & Clinical Cancer Research 2009, 28:38 http://www.jeccr.com/content/28/1/38
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Tomography) with FdG (fluoro-deoxy-glucose) or
Methionine in 4 other patients. In some cases, particularly
for patients affected by metastasis, who underwent sur-
gery for the differential diagnosis between tumor relapse
or radiation necrosis, the gold standard was histological
data and for the patients who did not undergo surgery a
three or six month follow-up, showing lesion regression
or tumor progression, was considered.
All the lesions included in this study, both primary and
secondary, were investigated by morphological MR, utiliz-
ing a superconductive magnet, operating at 0.5 T; SE
(spin-eco) technique and T1, T2-weighted and FLAIR
(Fluid Attenuated Inversion Recovery) sequences were
used before contrast medium infusion, after injection of a
double-dose of Gadolinium-DTPA (diethylenetriamine
penta-acetic acid), SE T1 sequences in axial, coronal and
sagittal planes were used.
CT perfusion technique
After un-enhanced CT of the whole brain to detect the
lesion, two adjacent 10 mm. thick sections were selected
in the area of interest, at level of the largest transverse
lesion dimension. The perfusion scan was performed after
the injection of 40 ml of non-ionic contrast agent contain-
ing 300 mg of iodine per ml (Iopamidol or Omnipaque;
Nycomed, Oslo, Norway), at an injection rate of 8 ml/s;
the time of total infusion by the automatic injector was 5
s. Four seconds after the injection began, a 40 s cine (con-
tinuous) scan with 1 s interval was acquired at the chosen
slice location.
The patients received the total effective dose equivalent to
1.1 mSv according to other values in the literature [10-12]
calculated by ImPACT CT Patient Dosimetry Calculator
(v. 0.99×, Medical Devices Agency, London).
Image analysis
CT perfusion data (40 grow images in a gray scale) were
analyzed and elaborated by a Siemens imaging worksta-
tion equipped with CT Perfusion; Access SOMATOM Sen-
sation 4 software (Version A47C) to yield coloured map
images.
The Anterior Cerebral Artery (ACA) or middle cerebral
artery (MCA) was selected as input artery, and a large
venous structure, such as the torcular herophili is chosen
as the input vein. Particular attention was given to the
selection of the arterial and venous input functions and to
the choice of the cut-off values for unenhanced and
enhanced images. To avoid partial volume effects a refer-
ence vessel large enough and sufficiently orthogonal to
the scan section was selected.
The elaborated images are represented by 11 parametric
maps: a standard set including the Maximum Intensity
Projection (MIP), Cerebral Blood Volume (CBV), Cere-
bral Blood Flow (CBF) and Time to Peak (Tpeak) maps and
an optional set including the Average Perfusion (Pmean),
Peak Enhancement (PeakEnh), Time to Start (Tstart), Perme-
ability (PS = permeability-surface area product), Patlak
Rsquare (PatRsq), Patlak Residual Perfusion (PatRes)and
Patlak Blood Volume (PBV).
The Peak Enhancement, Time to Start and to Peak Per-
fusion, Average Perfusion are semi-quantitative parame-
ters, readily obtained from the tumor attenuation curve
that reflects the tumor vascularity.
It is known that the perfusion can be calculated either
from the maximal slope of the tissue concentration-time
curve or from its peak height, normalized to the arterial
input function [13]. The modelling used by the commer-
cial software is based on compartmental analysis: a two
compartment model (intravascular equivalent to blood
and extravascular equivalent to tissue extracellular fluid)
is used by assuming the back flux of contrast medium
from extravascular to intravascular compartments to be
negligible for the first 1 to 2 min (a technique known as
Patlak analysis [14]).
On the basis of this theoretical model, the exchange
between the blood and the tissue can be well described by
the Patlak plot, representing the ratio of tissue to blood
concentration against the ratio of the AUC (area under
curve) of the blood curve to the blood concentration for
various time values. If the data are consistent with this the-
oretical model then the plot is linear (PatRsq R2  1 e
PatRes 2  0), with a slope equal to the blood clearance
per unit volume (Permeability) and an intercept equal to
the tissue's relative blood volume (PBV).
Both the elaborated and row images were exported by
means of the Digital Imaging and Communications in
Medicine (DICOM) protocol to a personal computer for a
post-processing procedure. This consists of a manual
selection of a ROI by an expert radiologist on the unen-
hanced CT scan, according to the alternative functional
imaging exams (MR or PET). In Fig. 1 the transverse CT
image and the CBV map in a patient with grade III astro-
cytoma, are shown; ROIs representing the lesion and the
contralateral region are displayed in black and white
respectively. To underline the variability in volume size of
tumors, another example of a patient, affected by a recur-
rence of glioblastoma, is shown in Fig. 2.
Quantitative analysis
Being completely digital, the images were suitable for
quantitative analyses, pixel per pixel. Home-made soft-Journal of Experimental & Clinical Cancer Research 2009, 28:38 http://www.jeccr.com/content/28/1/38
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ware has been developed using Matlab code (Release 6.5,
The Mathworks Inc., Natick, Massachusetts) to perform
quantitative analyses. This software permits the paramet-
ric maps obtained by CT perfusion data sets to be visual-
ized, displaying the data type (CBV or CBF etc.), the slice
position and the file name on each map. A graphic tool
was developed to allow the radiologist to place an arbi-
trary ROI on each image, obtaining the corresponding
area size and the mean value with its standard deviation
inside the drawn ROI. The side-to-side ratios of these val-
ues have been automatically calculated from mirrored
Transverse CT (Computer Tomography) image (a) and CBV  (Cerebral Blood Volume) map (b) in a patient with grade III  astrocytoma Figure 1
Transverse CT (Computer Tomography) image (a) 
and CBV (Cerebral Blood Volume) map (b) in a 
patient with grade III astrocytoma. In both the images, 
the hand-drawn ROI (region of interest) corresponding to 
the tumor and the contralateral ROI are displayed in black 
and white, respectively.
Transverse CT (Computer Tomography) image (a) and CBV  (Cerebral Blood Volume) map (b) in a patient affected by a  recurrence of glioblastoma Figure 2
Transverse CT (Computer Tomography) image (a) 
and CBV (Cerebral Blood Volume) map (b) in a 
patient affected by a recurrence of glioblastoma. In 
both the images, the hand-drawn ROI (region of interest) 
corresponding to the tumor and the contralateral ROI are 
displayed in black and white, respectively.Journal of Experimental & Clinical Cancer Research 2009, 28:38 http://www.jeccr.com/content/28/1/38
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regions in the contralateral hemisphere. Particular atten-
tion was paid to exclude that the automated contour of
the contralateral region included arterial or venous struc-
tures, altering data and affecting the subsequent statistical
analyses.
All elaborated data, corresponding to the mean values
with their standard deviations inside the outlined ROIs,
the contralateral ROIs and their ratios were recorded in an
output text file. These data were initially used to investi-
gate whether some perfusion parameters coming from CT
perfusion data could be useful to characterize the entire
patient group. Later, the diseased region (malignant gli-
oma or metastases), and the contralateral region (normal
tissue) were studied to find out if they could be differenti-
ated on the basis of some parametric maps. The more sig-
nificant parameters for differentiating between lesion and
normal tissue were obtained through a statistical analysis.
Statistical analysis
ROC analysis [15] was used to compare the accuracy of
the radiological tests in identifying and discriminating
diseased from normal cases in a five-point scale classifica-
tion (normal, benign, probably benign, probably malig-
nant and malignant. A ROC curve for these five decision
thresholds corresponding to the number of true positive,
true negative, false positive and false negative cases was
plotted.
In a ROC curve the Sensitivity (TPF: True Positive Frac-
tion) is plotted in function of the (1-Specificity) or (FPF:
False Positive Fraction), where Specificity is (TNF: True
Negative Fraction).
Only all the values of sensitivity/specificity pairs plotted
in the roc curve provides a complete picture of test accu-
racy and the area under the ROC curve (Az) is the measure
[16].
A computer software packages NCSS (Release NCSS2007,
Kaysville, Utah) was used to determine the statistical sig-
nificance (p-values) of the difference between the areas
under ROC curves with the relative standard error and
95% confidence interval.
In addition to ROC curves, parametric (t-test for inde-
pendent and paired samples) and non-parametric tests
(Wilcoxon Signed Ranks test) were also used to investigate
the statistically significant differences between diseased
and normal regions.
Results
Before evaluating the parametric maps, an analysis of the
tumor size was made for the patient population included
in this study. In Fig. 3 the histogram of the areas outlined
by the radiologist for each patient as malignant region has
been displayed. The average area being 157.0 mm2 and
the range was 48.6–520.0 mm2. This analysis was per-
formed on the evidence that the great variability in ROI
size surely has a great impact on the mean perfusional val-
ues and their variability inside ROIs (see also Fig. 1, 2).
Using perfusion maps to find the possible predictors of
malignancy, an analysis was performed on 22 patients
affected by a malignant glioma or metastases. The mean
values and the standard deviations of all the parameters
inside the ROIs delineated by the radiologist as lesions
and inside the contralateral ROIs were calculated and
shown in Table 2 (Tstart was not included being considered
of minor interest for the aim of the study).
Both parametric (t-test) and non-parametric tests (Wil-
coxon Signed Ranks test) were used to perform the study,
and the t-test was executed with the hypothesis of both
independent and paired samples to exclude the possibility
that the values obtained inside the contralateral ROIs
could be affected by the presence of a tumor on the other
hemisphere (Tab. 3). The non-parametric Wilcoxon
Signed Ranks test was performed, as, due to the limited
number of patients it could not be established with cer-
tainty whether the probability distribution underlying
data was normal, results are displayed in Table 4.
The ROC curves of parameters found to be statistically sig-
nificant, PatRsq, PS and Tpeak (actually this parameter gave
a p slightly superior to 0.05) have also been generated. In
Table 5 ROC curve areas and 95% confidence intervals for
PatRsq, PS and Tpeak were reported. By means of the univar-
iate z-score test, it was determined the statistical signifi-
cance (pz value = 0.05) of the difference between each
ROC curve and the reference line (diagonal) with area
equal to 0.5. The z-test results were also shown in Table 5.
Only the ROC curves of PatRsq and PS, found to have a sig-
nificant predictive value for differentiating between
malignant and normal tissue were displayed in Fig. 4. The
curves are based on the binormal assumption, that was
previously verified performing the Kolmogorov-Smirnov
normality test. No statistical significant difference was
found between the two ROC curves.
To investigate the relationships between the variables
found to be significantly correlated with malignancy, a
Spearman correlation study was performed (Table 6).
Only PatRsq and PS resulted correlated, the R coefficient
being equal to 0.876.
A plot of PatRsq versus PS is displayed in Fig. 5, showing a
strong correlation between these variables.Journal of Experimental & Clinical Cancer Research 2009, 28:38 http://www.jeccr.com/content/28/1/38
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Histogram of the areas outlined by the radiologist, for each patient, as malignant regions Figure 3
Histogram of the areas outlined by the radiologist, for each patient, as malignant regions.
Table 2: Average values and standard deviations of all the perfusional parameters for malignant and normal tissue.
PatRes(1:1000) PatRsq(1:100) PS(0.5 ml/100 ml/min) PBV(%) Tpeak(s)
Normal Tissue 9.0 ± 5.7 8.5 ± 9.0 4.2 ± 6.9 3.3 ± 1.6 5.4 ± 2.2
Lesion 10 ± 5.3 34.6 ± 29.3 14.2 ± 12.6 4.0 ± 1.8 7.5 ± 2.7
CBV(%) Peakenh(a.u.) CBF(ml/100 ml/min) Pmean(a.u.) MIP(a.u.)
Normal Tissue 4.3 ± 3.2 7.8 ± 8.3 30.9 ± 24.7 35.8 ± 15.0 50.0 ± 16.2
Lesion 6.3 ± 5.0 10.9 ± 8.0 38.8 ± 40.0 42.9 ± 15.0 55.7 ± 12.5
The relative units are indicated in brackets (a.u. is an abbreviation for arbitrary units).Journal of Experimental & Clinical Cancer Research 2009, 28:38 http://www.jeccr.com/content/28/1/38
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Discussion
Dynamic perfusion imaging with CT or MR is based on
the imaging evaluation of biodistribution of the contrast
medium infusion acting as a tracer. The contrast medium
after infusion is distributed into the tissue in relation to
local microvascularization and on the diffusion across the
endothelial membrane into the interstitial space. The
imaging depicts the distribution of the contrast medium
by measuring variations in the vessels and in the tissue
enhancement over time. Tissue is composed of three com-
partments: vascular (capillaries), interstitial and intracel-
lular compartments; the contrast medium used in clinical
practice has interstitial diffusion; the interstitial compart-
ment represent the volume into which the contrast dif-
fuses while this contrast does not penetrate the cells or
blood cells.
In this study, CT-Perfusion imaging of brain tumors was
used to characterize brain tumors and metastases, analyz-
ing the perfusional maps of 22 patients affected by a
malignant glioma or metastasis. Always the same radiolo-
gist (A.V.) outlined the ROIs identifying the tumor, to
reduce the inter-observer variability. In fact, it has been
assessed by other authors [17] that the variability in mean
quantitative values of CBF, CBV and MTT was less than
9%, among a group of 6 observers with varying levels of
skill.
It turned out that tumors are characterized by higher val-
ues of all the perfusion parameters, including CBV and
CBF, but, after both parametric and non-parametric statis-
tical tests, only the PS, PatRsq and Tpeak resulted relevant to
identify a neoplastic tissue. In particular, the PS, PatRsq
and Tpeak were on average 3.4, 4 and 1.4 higher for the
tumor than for normal tissue, respectively (Table 2). From
the high standard deviations of all the parameters it can be
inferred that a great variability exists among patients, both
inside normal and malignant tissues, as evidenced by
other authors [10].
The increased vascular proliferation of the tumor and the
hypothesis that feeding arterioles in neoplastic tissue are
more vasodilated than in normal tissue are largely sup-
ported by previous studies [7-9] and can also explain our
findings.
Because of the short scan duration (45 s), the perfusion
and blood volume represent the more accurate maps; in
fact a study of vascular permeability should have required
a scan time up to 2 to 10 min, as suggested by Miles et al.
[18]. Nevertheless the parameter PS resulted the most sen-
sitive to tissue changes from a normal to malignant state,
even if acquired for a partial time. Anyway, several studies
reported measurements of vascular permeability using CT
scan duration only slightly longer than that one used in
the present work [7,19,20].
Probably due to the high standard deviation of our data,
reflecting the high heterogeneity of tumor, some parame-
ters did not show the expected predictive power. In fact, in
the majority of cases, the region outlined by the radiolo-
gist as malignant appears spatially inhomogeneous, with
areas of vascular proliferation and areas of necrosis. The
presence of necrotic tissue inside the lesion, in particularly
in high-grade gliomas and large metastases, surely affects
data, decreasing the average values of blood volume, flow
and permeability. It can be supposed that, for these rea-
sons, some parameters such as CBV and CBF did not
appear to be significant for identifying the lesion, contrary
Table 3: Results of paired samples t-tests, performed to compare 
the average perfusional values inside the lesion with those inside 
the contralateral region.
Paired Samples t-test
PatRes PatRsq PS PBV Tpeak
t 1.599 3.851 4.161 1.931 2.103
P 0.132 0.002 0.000 0.068 0.054
CBV Peakenh CBF Pmean MIP
t 1.727 1.008 0.912 1.443 1.391
P 0.106 0.331 0.376 0.171 0.179
P-values < 0.05 are evidenced in bold.
Table 4: Results of Wilcoxon Signed Ranks Test, performed to 
compare the average perfusional values inside the lesion with 
those inside the contralateral region.
PatRes PatRsq PS PBV Tpeak
T -1.526 -3.234 -3.564 -1.625 -1.853
P 0.127 0.001 0.000 0.104 0.064
CBV Peakenh CBF Pmean MIP
T -1.563 -1.415 -0.750 -0.909 -0.974
P 0.118 0.157 0.453 0.363 0.330
P-values < 0.05 are evidenced in bold.
Table 5: Areas under the Receiving Operating Characteristic 
curves (Az), 95% confidence intervals and results of the Z test for 
PatRsq (Patlak Rsquare), PS (Permeability-surface area product) 
and Tpeak (Time to Peak).
Az ± SE 95% Confidence interval pz
PatRsq 0. 82 ± 0.08 0.58 ÷ 0.93 0.02
PS 0.81 ± 0.09 0.57 ÷ 0.92 0.02
Tpeak 0.68 ± 0.10 0.44 ÷ 0.83 0.12
P-values < 0.05 and the related Az are evidenced in bold.Journal of Experimental & Clinical Cancer Research 2009, 28:38 http://www.jeccr.com/content/28/1/38
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to the results of other authors [7-9]. The complexity of the
microvascular environment of tumor is clearly shown by
the blood volume maps (see Fig. 1, 2): for some patients,
the outlined ROIs are very large, with areas up to 500.0
mm2, as demonstrated by the histogram in Fig. 3.
Nevertheless, this variability allowed us to identify among
the perfusion maps those having the highest prognostic
power. Using the ROC curves, it was possible to establish
the predictive value of each parameter that resulted statis-
tically significant: PS, PatRsq and Tpeak. Both PatRsq and PS
were confirmed to be equally reliable metrics for discrim-
inating between malignant and normal tissues, with
AUCs of 0.82 and 0.81 respectively, and pz value of 0.02.
Instead, Tpeak was not found to be significant, with an AUC
of 0.68 and pz value of 0.11.
The strong relation between PS and PatRsq has also been
confirmed by the Spearman correlation coefficient (Table
6) and the scatter plot in Fig. 5.
The perfusion studies, both with CT and or MRI, consid-
ered by recent studies, can be used for preoperative grad-
ing of the gliomas, in particularly for the differential
diagnosis of low and high-grade astrocitomas because
these technique can provide complementary information
Receiving Operating Characteristic (ROC) curves of parameters were significant for predicting the presence of malignant tis- sue (the diagonal represents the reference line with area equal to 0.5) Figure 4
Receiving Operating Characteristic (ROC) curves of parameters were significant for predicting the presence 
of malignant tissue (the diagonal represents the reference line with area equal to 0.5).
Table 6: Spearman's correlation coefficients R and p-values to 
measure how PatRsq (Patlak Rsquare), PS (Permeability-surface 
area product) and Tpeak (Time to Peak) are related.
PS Tpeak
PatRsq R 0.876 0.257
p 0.000 0.178
P-values < 0.05 are evidenced in bold.Journal of Experimental & Clinical Cancer Research 2009, 28:38 http://www.jeccr.com/content/28/1/38
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about tumor hemodynamics, not available with conven-
tional CT or MR. The potential role of these techniques in
follow-up analysis, lies in the differential diagnosis
between radiation necrosis and recurrence in patients
who have undergone radiotherapy and in the evaluation
of the response to the anti-angiogenetic therapy, and its
ability to detect the biological effects to treatment by
depicting early microvascularization modifications,
related to a reduction in microvessel density, before
tumor dimension modifications [21-24].
Conclusion
Tumors are characterized by higher values of all the per-
fusion parameters. Using statistical analyses both the PS
and PatRsq resulted significant for discriminating between
malignant and normal tissue, with comparable prognostic
power.
Additional studies, including a greater quantity of data, to
differentiate between the patients with high and low grade
tumors, or those with radionecrosis and recurrence are
warranted.
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Plot of PatRsq (Patlak Rsquare) versus PS (Permeability-surface area product), showing the strong correlation between variables,  as confirmed by the Spearman's correlation coefficient equal to 0.876 Figure 5
Plot of PatRsq (Patlak Rsquare) versus PS (Permeability-surface area product), showing the strong correlation 
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scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Experimental & Clinical Cancer Research 2009, 28:38 http://www.jeccr.com/content/28/1/38
Page 10 of 10
(page number not for citation purposes)
Authors' contributions
AMDN and MC conceived of the study and partecipated
in its design and coordination. AV carried out the per-
fusion CT exams. SM performed the statistical analyses
and partecipated in the draft of the manuscript. AF, AP
and CMC contributed with the enrollement of patients; in
particular CMC enrolled those patients undergoing a sur-
gery or stereotactic biopsy. AM partecipated in the design
of the study and selected those patients eligible for a radi-
otherapy treatment. All authors read and approved the
final draft.
Acknowledgements
The authors are indebted to Fabio Portieri for his continued technical 
assistance, to the Nuclear Medicine Department for their collaboration and 
Mrs P.I. Franke for her assistance with the English transcript.
References
1. Boone JM: Radiological interpretation 2020: Toward quantita-
tive image assessment.  Med Phys 2007, 34:4173-4179.
2. Roberts HC, Roberts TPL, Lee TY, Dillon WP: Dynamic, Con-
trast-Enhanced CT of human brain tumors: quantitative
assessment of blood volume, blood flow, and microvascular
permeability: Report of two cases.  AJNR 2002, 23:828-832.
3. Di Nallo AM, Crecco M, Ortenzia O, Ordonez R, Abate A, Benassi
M: The breast dynamic contrast enhanced MRI: Preliminary
results of a quantitative analysis.  J Exp Clin Cancer Res 2007,
26:235-239.
4. Miles KA, Griffiths MR: Perfusion CT: a worthwhile enhance-
ment?  Br J Radiol 2003, 76:220-31.
5. Hoeffner EG, Case I, Jain R, Gujar SK, Shah GV, Deveikis JP, Carlos
RP, Thompson BG, Harrigan MR, Mukherji SK: Cerebral Perfusion
CT: Technique and Clinical applications.  Radiology 2004,
231:632-644.
6. Eastwood JD, Provenzale JM: Cerebral blood flow, blood volume
and vascular permeability of cerebral glioma assessed with
dynamic CT perfusion imaging.  Neuroradiology 2003,
45:373-376.
7. Ding B, Ling HW, Chen KM, Jiang H, Zhu YB: Comparison of cer-
ebral blood volume and permeability in preoperative grad-
ing of intracranial glioma using CT perfusion imaging.
Neuroradiology 2006, 48:773-781.
8. Jain R, Ellika SK, Scarpace L, Schultz LR, Rock JP, Gutierrez J, Patel J,
Ewing SC, Mikkelsen T: Quantitative Estimation of Permeabil-
ity Surface-Area Product in Astroglial Brain Tumors Using
Perfusion CT and Correlation with Histopathologic Grade.
AJNR 2008, 29:694-700.
9. Cenic A, Nabavi DG, Craen RA, Gelb AW, Lee TY: A CT Method
to Measure Hemodynamics in Brain Tumors: Validation and
Application of Cerebral Blood Flow Maps.  AJNR 2000,
21:462-470.
10. Brix G, Bahner ML, Hoffmann U, Horvath A, Schreiber W: Regional
Blood Flow, Capillary Permeability, and Compartmental
Volumes: Measurement with Dynamic CT – Initial Experi-
ence.  Radiology 1999, 210:269-276.
11. Sahani DV, Kalva SP, Hamberg LM, Hahn PF, Willett CG, Saini S, Muel-
ler PR, Lee T: Assessing Tumor Perfusion and Treatment
Response in Rectal Cancer with Multisection CT: Initial
Observations.  Radiology 2005, 234:785-792.
12. Molen AJ Van Der, Veldkamp WJH, Geleijns J: 16-slice CT: achiev-
able effective doses of common protocols in comparison
with recent CT dose surveys.  British Journal of Radiology 2007,
80:248-255.
13. Axel L: Cerebral blood flow determination by rapid-sequence
computed tomography.  Radiology 1980, 137:679-686.
14. Patlak CS, Blasberg RG: Graphical evaluation of blood-to-brain
transfer constants from multiple-time uptake data. General-
izations.  J Cereb Blood Flow Metab 1985, 5:584-590.
15. Metz CE: Some practical issues of experimental design and
data analysis in radiological ROC studies.  Invest Radiol 1989,
24:234-245.
16. Van Erkel AR, Pattynaia PM: Receiver operating characteristic
(ROC) analysis: Basic principles and applications in radiol-
ogy.  Eur J Radiol 1998, 27:88-94.
17. Sanelli PC, Nicola G, Tsiouris AJ, Ougorets I, Knight C, Frommer B,
Veronelli S, Zimmerman RD: Reproducibility of Postprocessing
of Quantitative CT Perfusional Maps.  Neuroradiology 2007,
188:213-218.
18. Miles KA: Perfusion CT for the assessment of tumor vascular-
ity: which protocol?  Br J Radiol 2003, 76:S36-S42.
19. Newbold K, Castellano I, Charles-Edwards E, Mears D, Sohaib A,
Leach M, Rhys-Evans P, Clarke P, Fisher C, Harrington K, Nutting C:
An exploratory study into the role of dynamic contrast-
enhanced magnetic resonance imaging or perfusion com-
puted tomography for detection of intratumoral hypoxia in
head-and-neck cancer.  Int J Radiation Oncology Biol Phys 2008 in
press.
20. Bisdas S, Nguyen SA, Anand SK, Glavina G, Day T, Rumboldt Z: Out-
come prediction after surgery and chemoradiation of squa-
mous cell carcinoma in the oral cavity, oropharynx, and
hypopharinx: use of baseline perfusion CT microcirculatory
parameters vs. tumor volume.  Int J Radiation Oncology Biol Phys
2007 in press.
21. Schmainda KM, Rand SD, Joseph AM, Lund R, Ward BD, Pathak AP,
Ulmer JL, Baddrudoja MA, Krouwer HGJ: Characterization of a
First-Pass Gradient-Echo Spin-Echo Method to Predict Barin
Tumor Grade and Angiogenesis.  AJNR 2004, 25:1524-1532.
22. Sugahara T, Korogi Y, Tomiguchi S, Shigematsu Y, Ikushima I, Kira T,
Liang L, Ushio Y, Takahashi M: Posttherapeutic Intraaxial Brain
Tumor: The Value of Perfusion-sensitive Contrast-enhanced
MR Iamging for Differentiating Tumor Recurrence from
Nonneoplastic Contrast-enhancing Tissue.  AJNR 2000,
21:901-909.
23. Li KL, Zhu XP, Checkley DR, Tessier JJL, Hillier VF, Waterton JC,
Jackson A: Simultaneous mapping of blood volume and
endothelial permeability surface area product in gliomas
using iterative analysis of first-pass dynamic contrast
enhanced MRI data.  The British Journal and Radiology 2003,
76:39-50.
24. Zima A, Carlos R, Gandhi D, Case I, Teknos T, Mukherji SK: Can
Pretreatment CT Perfusion Predict Response of Advanced
Squamous Cell Carcinoma of the Upper Aerodigestive
Tract Treated with Induction Chemotherapy?  AJNR 2007,
28:328-334.